1. Home
  2. /
  3. Projects

Accessibility

Accessibility refers to equitable delivery aimed at all who could benefit from a new TB vaccine for adults and adolescents. This includes defined implementation strategies, having delivery systems and sustainable financing strategies in place. This follows from the WHO global framework for country introduction of new adolescent and adult TB vaccines (https://www.who.int/publications/m/item/who-global-framework-to-prepare-for-country-introduction-of-new-tb-vaccines-for-adults-and-adolescents)

TBVacMod

Ongoing
Estimate the health impact of introducing a prevention of disease vaccine for adult and adolescents in moderate to high TB burden countries. Explore different vaccine introduction scenarios based on input from country stakeholders, including national TB program and immunization program officials, on priority groups for vaccination and likely vaccine coverage. The project's key questions include: 1) who are the priority groups in different countries and what is expected level of vaccine coverage in those groups 2) how will vaccine impact differ in different introduction scenarios (vary age, priority group, coverage)

Supporting countries with prioritization of new vaccine introductions (NVI) and portfolio optimization

Ongoing
Support countries with using multi-criteria decision analysis (MCDA) for prioritization of new vaccine introductions (NVI) (including new TB vaccines) and portfolio optimization, embedded in the NIS development process. The project's key questions are: 1. How can we best support countries with NVI including new TB vaccine prioritization regarding access to evidence, tools, technical support? 2. What criteria do countries use when prioritizing NVIs? 3. How to best align NVI prioritization with the NIS development process.

Protecting investment in TB vaccine R&D and health systems amid debt distress and reform

Ongoing
IMF analysis reveals 51 countries with moderate-to-high risk of sovereign debt distress and 9 countries in debt distress: unable to fulfill financial obligations to lenders. For many high-TB burden countries, yearly debt servicing now exceeds domestic revenue – forcing countries to cut expenditure on health. Based on a literature review and engagement with World Bank/IMF, this abstract presents a policy analysis of the implications of sovereign debt distress on TB vaccine readiness and proposes debt relief and reform as innovative financial tools for creating fiscal space for government investment in vaccine R&D and implementation

IAVI

Ongoing
1. Understand likely use cases, delivery strategies, target populations, and drivers of preference and adoption; 2. Project demand; 3. Evaluate potential willingness to pay and budget impact; 4. Explore innovative financing mechanisms;

Global TB vaccine partnership

2011-2023
Ongoing
The Global Tuberculosis Vaccine Partnership (GTBVP) is a forum for key stakeholders in TB vaccine R&D to identify and address barriers impeding TB vaccine R&D and to discuss R&D priorities in order to help inform funding decisions

TB vaccine advocacy roadmap

2021
Ongoing
The TB Vax ARM represents a global coalition of TB stakeholders, including TB survivors, civil society organizations, and non-profits, invested in TB vaccine advocacy and research, and seeks to provide coordinated advocacy efforts that are complementary to ongoing TB vaccine R&D and policy efforts. The TB Vax ARM holds regular virtual calls with partners and guest speakers from around the world. WGNV coordinates with the TB Vax ARM on global advocacy activities. For more information go to: https://newtbvaccines.org/take-action/
Load More
Click to copy link of this header Menu